Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus.
Détails
Télécharger: 34203936_BIB_79BF1AA9A2FD.pdf (763.93 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_79BF1AA9A2FD
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus.
Périodique
Microorganisms
ISSN
2076-2607 (Print)
ISSN-L
2076-2607
Statut éditorial
Publié
Date de publication
15/06/2021
Peer-reviewed
Oui
Volume
9
Numéro
6
Pages
1306
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Publication Status: epublish
Résumé
Ecological changes, population movements and increasing urbanization promote the expansion of hantaviruses, placing humans at high risk of virus transmission and consequent diseases. The currently limited therapeutic options make the development of antiviral strategies an urgent need. Ribavirin is the only antiviral used currently to treat hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), even though severe side effects are associated with this drug. We therefore investigated the antiviral activity of favipiravir, a new antiviral agent against RNA viruses. Both ribavirin and favipiravir demonstrated similar potent antiviral activity on HTNV infection. When combined, the efficacy of ribavirin is enhanced through the addition of low dose favipiravir, highlighting the possibility to provide better treatment than is currently available.
Mots-clé
Hantaan virus, combination therapy, favipiravir, ribavirin
Pubmed
Web of science
Open Access
Oui
Création de la notice
09/07/2021 9:47
Dernière modification de la notice
08/08/2024 6:35